Ligand

Schrödinger Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 2, 2023
Health, Technology, Software, General Health, Pharmaceutical, Biotechnology, Myelodysplastic syndrome, Gastrointestinal disease, CDC7, Type 2 diabetes, Obesity, Table, Lymphoid leukemia, Ligand, Pharmacokinetics, GAAP, ID, Ulcerative colitis, Psoriasis, Acute myeloid leukemia, MALT1, Patient, Investment, TYK2, Drug discovery, FDA, Therapy, IND, Safety, Pharmaceutical industry, Video game, Bank

Operating expense growth in 2023 is expected to be significantly lower than operating expense growth in 2022.

Key Points: 
  • Operating expense growth in 2023 is expected to be significantly lower than operating expense growth in 2022.
  • Cash used for operating activities in 2023 is expected to be below cash used for operating activities in 2022.
  • For the third quarter of 2023, software revenue is expected to range from $27 million to $31 million.
  • Schrödinger will host a conference call to discuss its second quarter 2023 financial results on Wednesday, August 2, 2023, at 4:30 p.m.

Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

Retrieved on: 
Thursday, July 27, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, MSD, Vaccine, CRM197, Merck, OPA, Pelican, Ligand

If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.

Key Points: 
  • If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.
  • Additionally, results from STRIDE-6 demonstrated that V116 was immunogenic for all 21 pneumococcal serotypes in the vaccine among adults who previously received a pneumococcal vaccine at least one year prior to the study.
  • V116 utilizes the CRM197 vaccine carrier protein, which is produced using Ligand’s patent-protected Pelican Expression Technology™ platform.
  • “We are delighted to see Merck’s continued progress with V116 and their pneumococcal conjugate vaccine franchise,” said Todd Davis, CEO of Ligand.

Ligand Offers $15 Million to Acquire Assets of Novan, Inc.

Retrieved on: 
Monday, July 17, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, EPI, Fungal infection, Chapter 11, Title 11, United States Code, DIP, Sale, Stalking, Food and Drug Administration, Acquisition, Molluscum contagiosum, PDUFA, FDA, Food, Bankruptcy, Cryptocurrency, Credit, Novin, Ligand

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has made an offer to acquire the assets of Novan, Inc. (Nasdaq: NOVN) (“Novan”) for $15 million in cash and provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has made an offer to acquire the assets of Novan, Inc. (Nasdaq: NOVN) (“Novan”) for $15 million in cash and provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded.
  • Novan announced earlier today that it has filed for Chapter 11 reorganization and its entry into a stalking horse acquisition offer with Ligand.
  • The transaction is designed to preserve and maximize the value of Novan’s commercial business and berdazimer gel development assets.
  • We are well positioned to take advantage of opportunities such as the proposed acquisition of Novan’s assets,” said Todd Davis, CEO of Ligand.

SandboxAQ Announces Bio-Pharma Molecular Simulation Division to Speed Life-Saving Drugs to Patients Through AI and Quantum Solutions

Retrieved on: 
Saturday, June 24, 2023
DMRG, San Francisco, TPU, Partnership, Post, PALO, Columbia University Irving Medical Center, Ligand, Pulitzer Prize, University of California, San Francisco, Cancer, Research, AstraZeneca, Drug design, AQ, DFT, Alzheimer's disease, Pulitzer, Parkinson's disease, UC, MD, UCSF, Patient, Drug discovery, Sanofi, Neurodegenerative disease, AI, Fine chemical, Pharmaceutical industry, Medical device

PALO ALTO, Calif., June 23, 2023 /PRNewswire-PRWeb/ --  After several years of stealth development, SandboxAQ today formally announced its bio-pharma molecular simulation division, AQBioSim, and some of its customers and partners. The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer's, Parkinson's, and other conditions. The company is collaborating with a range of bio-pharma companies and university research labs, including AstraZeneca, Sanofi and UC San Francisco.

Key Points: 
  • The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer's, Parkinson's, and other conditions.
  • Paul Hudson, CEO of Sanofi said, "We are very interested in the work SandboxAQ is doing to revolutionize drug discovery and development via in-silico simulation of molecular interactions using AI and quantum technologies.
  • "SandboxAQ is at the forefront of combining AI and quantum techniques to address large, enterprise challenges.
  • SandboxAQ's technology is revolutionizing the drug discovery and development process," said Eric Schmidt, Chairman of the Board of SandboxAQ."

Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Retrieved on: 
Wednesday, June 21, 2023
Society, Mayo Clinic, University, MC1R, Neoplasm, Fortis Healthcare, Glomus tumor, Molecular imaging, Ligand, Cancer, Lead, Fast Track, Research, PB, Perspective, Immunotherapy, Teaching hospital, CDMO, CATX, Patient, Melanoma, FMRI, SSTR2, Therapy, IND, Isotope, NYSE, Pharmaceutical industry, Medical imaging, IOWA

The first product candidate, VMT-α-NET, is a result of Perspective’s intensive in-house research and development efforts to develop a best-in-class radiopeptide.

Key Points: 
  • The first product candidate, VMT-α-NET, is a result of Perspective’s intensive in-house research and development efforts to develop a best-in-class radiopeptide.
  • Both US trials will be supplied with finished drug product from Perspective’s GMP manufacturing facility in Coralville, IA.
  • “These clinical trials represent a significant advancement in our relentless pursuit of innovative and potent treatments for cancer," said Markus Puhlmann, Chief Medical Officer at Perspective.
  • The targeted alpha-particle therapies that are being developed at Perspective have the potential to revolutionize the treatment of these and many other cancers.

ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential

Retrieved on: 
Wednesday, June 21, 2023
BIO, Drug development, Gene, The, Doctor of Philosophy, Half-life, Drug discovery, Neoplasm, Ligand, Fusion, Cancer, Drug, ART, Bayer, Patient, Cell, Ecosystem, Regulatory affairs, Biotechnology Innovation Organization, Prostate cancer, Pharmaceutical industry, Medical imaging, Bruland

CAMBRIDGE, Mass. and OSLO, Norway and LONDON and BASEL, Switzerland, June 21, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), announced its founding with a $23 million seed financing led by F-Prime Capital with Omega Funds. ARTBIO was founded in 2021 by Roy Larsen, Øyvind Bruland, Radforsk, and F-Prime Capital to create highly targeted cancer therapies by pairing the optimal alpha-emitting isotope Pb212 with ligands against proven tumor-specific targets. ARTBIO is also creating an entirely new approach to ART manufacturing to overcome production and distribution challenges. In early 2022, Emanuele Ostuni, formerly Head of Europe for Cell and Gene Therapy at Novartis Oncology, joined ARTBIO as CEO to start building its world-class team and advance its proprietary technology, while securing additional funding from F-Prime Capital and Omega Funds.

Key Points: 
  • ARTBIO is also creating an entirely new approach to ART manufacturing to overcome production and distribution challenges.
  • "Our unique approach combines Pb212 best in class properties with rationally designed ligands against tumor-specific targets to unlock the full therapeutic potential of alpha radioligand therapy," said Emanuele Ostuni, Ph.D., Chief Executive Officer of ARTBIO.
  • Vicki Jardine, M.D., Ph.D., Vice President of Clinical Development; Former Senior Clinical Development Leader (Alpha Radioligand Therapies) at Bayer
    Ted W. Love, M.D.
  • "Roy and Øyvind are serial entrepreneurs responsible for developing the only alpha particle emitting radiopharmaceutical product currently on the market.

ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential

Retrieved on: 
Wednesday, June 21, 2023
BIO, Drug development, Gene, The, Doctor of Philosophy, Half-life, Drug discovery, Neoplasm, Ligand, Fusion, Cancer, Drug, ART, Bayer, Patient, Cell, Ecosystem, Regulatory affairs, Biotechnology Innovation Organization, Prostate cancer, Pharmaceutical industry, Medical imaging, Bruland

CAMBRIDGE, Mass. and OSLO, Norway and LONDON and BASEL, Switzerland, June 21, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), announced its founding with a $23 million seed financing led by F-Prime Capital with Omega Funds. ARTBIO was founded in 2021 by Roy Larsen, Øyvind Bruland, Radforsk, and F-Prime Capital to create highly targeted cancer therapies by pairing the optimal alpha-emitting isotope Pb212 with ligands against proven tumor-specific targets. ARTBIO is also creating an entirely new approach to ART manufacturing to overcome production and distribution challenges. In early 2022, Emanuele Ostuni, formerly Head of Europe for Cell and Gene Therapy at Novartis Oncology, joined ARTBIO as CEO to start building its world-class team and advance its proprietary technology, while securing additional funding from F-Prime Capital and Omega Funds.

Key Points: 
  • ARTBIO is also creating an entirely new approach to ART manufacturing to overcome production and distribution challenges.
  • "Our unique approach combines Pb212 best in class properties with rationally designed ligands against tumor-specific targets to unlock the full therapeutic potential of alpha radioligand therapy," said Emanuele Ostuni, Ph.D., Chief Executive Officer of ARTBIO.
  • Vicki Jardine, M.D., Ph.D., Vice President of Clinical Development; Former Senior Clinical Development Leader (Alpha Radioligand Therapies) at Bayer
    Ted W. Love, M.D.
  • "Roy and Øyvind are serial entrepreneurs responsible for developing the only alpha particle emitting radiopharmaceutical product currently on the market.

IBC Launches Full Range of Best-in-Class Molecular Recognition Technology™ (MRT™) Flowsheets for Highly Selective Separations of Key Radionuclides and Preparation of Novel Chelating Agents for Radionuclide Incorporation into Radiopharmaceuticals

Retrieved on: 
Tuesday, June 20, 2023
Molecular recognition, Caesium, IBC, Metal, Radionuclide, Strontium, Ligand, Regeneration, Multimedia, Process flowsheeting, Radiopharmaceutical, EDS, Noetics, Izatt, Chelation, Elemental analysis, Mining, Wiley-VCH, Green chemistry, Conference, Peptide, Medical imaging, Palladium, Engineered wood, Fine chemical, Uranium mining, Seawater

IBC works closely with each customer to design, build, and commission a customized separation system to meet their needs.

Key Points: 
  • IBC works closely with each customer to design, build, and commission a customized separation system to meet their needs.
  • IBC is an award-winning manufacturer and supplier of highly selective separations products, engineered systems and processes based on Molecular Recognition Technology™ (MRT™.)
  • Industrial Applications of Molecular Recognition Technology to Green Chemistry Separations of Platinum Group Metals and Selective Removal of Metal Impurities from Process Streams.
  • Green Chemistry Molecular Recognition Processes Applied to Metal Separations in Ore Beneficiation, Element Recycling, Metal Remediation, and Elemental Analysis.

IBC Launches Full Range of Best-in-Class Molecular Recognition Technology™ (MRT™) Flowsheets for Highly Selective Separations of Key Radionuclides and Preparation of Novel Chelating Agents for Radionuclide Incorporation into Radiopharmaceuticals

Retrieved on: 
Tuesday, June 20, 2023
Molecular recognition, Caesium, IBC, Metal, Radionuclide, Strontium, Ligand, Regeneration, Process flowsheeting, Radiopharmaceutical, EDS, Noetics, Izatt, Chelation, Elemental analysis, Mining, Wiley-VCH, Green chemistry, Conference, Peptide, Medical imaging, Palladium, Engineered wood, Fine chemical, Uranium mining, Seawater

IBC works closely with each customer to design, build, and commission a customized separation system to meet their needs.

Key Points: 
  • IBC works closely with each customer to design, build, and commission a customized separation system to meet their needs.
  • IBC is an award-winning manufacturer and supplier of highly selective separations products, engineered systems and processes based on Molecular Recognition Technology™ (MRT™.)
  • Industrial Applications of Molecular Recognition Technology to Green Chemistry Separations of Platinum Group Metals and Selective Removal of Metal Impurities from Process Streams.
  • Green Chemistry Molecular Recognition Processes Applied to Metal Separations in Ore Beneficiation, Element Recycling, Metal Remediation, and Elemental Analysis.

Mercury Bio Accelerates Biomedical Research with Support from Los Alamos National Laboratory

Retrieved on: 
Thursday, June 15, 2023
Learning, Hermann Mucke (bioscientist), Mercury, Bio, Biotechnology, Ligand, CRADA, Los Alamos National Laboratory, Innovation, Research, Development, Cooperative research and development agreement, LANL, Disease, Pharmaceutical industry, AI

SANTA FE, N.M., June 15, 2023 /PRNewswire/ -- Mercury Bio (www.mercurybio.com) was recently awarded technical maturation assistance through the Technology Readiness Initiative (TRGR) from Los Alamos National Laboratory (LANL) and the Richard P. Feynman Center for Innovation to support an ongoing research collaboration between Mercury Bioscientists and Los Alamos. This research focuses on developing a computational modeling system for the design of membrane-attached targeting ligands, which will ultimately be incorporated into the Advanced Drug Delivery System (ADDS™) being developed by Mercury Bio. The TRGR marks a second phase of collaboration between the two entities, allowing them to build upon joint efforts made under an earlier Cooperative Research and Development Agreement (CRADA) grant.

Key Points: 
  • SANTA FE, N.M., June 15, 2023 /PRNewswire/ -- Mercury Bio ( www.mercurybio.com ) was recently awarded technical maturation assistance through the Technology Readiness Initiative (TRGR) from Los Alamos National Laboratory (LANL) and the Richard P. Feynman Center for Innovation to support an ongoing research collaboration between Mercury Bioscientists and Los Alamos.
  • This research focuses on developing a computational modeling system for the design of membrane-attached targeting ligands, which will ultimately be incorporated into the Advanced Drug Delivery System (ADDS™) being developed by Mercury Bio.
  • Current techniques for developing targeting ligands rely on heuristic methodologies, which can be time-consuming, expensive, and depend on past precedent to guide research.
  • Bruce McCormick, the CEO of Mercury Bio, says, "Working with the world-renowned Los Alamos National Laboratory scientists to develop this powerful new method for ligand design will enable new drugs to selectively target disease afflicted regions, directly manipulate disease mechanisms, and provide therapy for formerly untreatable diseases.